Euroapi S.A.S.U. (940)
Market Closed
12 Jun, 06:06
€
1. 31
+0.04
+3.4865%
€
- Market Cap
15.65 P/E Ratio
- Div Yield
0 Volume
0 Eps
€ 1.26
Previous Close Want to track 940 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
940 closed Friday higher at €1.31, an increase of 3.4865% from Thursday's close, completing a monthly decrease of -11.9946% or -€0.18. Over the past 12 months, 940 stock lost -42.467%.
940 is not paying dividends to its shareholders.
The last earnings report, released on Mar 03, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.1%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on XPAR (EUR).
940 Chart
Euroapi S.A.S.U. (940) FAQ
What is the stock price today?
The current price is €1.31.
On which exchange is it traded?
Euroapi S.A.S.U. is listed on XMUN.
What is its stock symbol?
The ticker symbol is 940.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Euroapi S.A.S.U. ever had a stock split?
No, there has never been a stock split.
Euroapi S.A.S.U. Profile
| Pharmaceuticals Industry | Healthcare Sector | Mr. David Seignolle CEO | XMUN Exchange | FR0014008VX5 ISIN |
| FR Country | 2,961 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Euroapi S.A., based in Paris, France, is an innovative pharmaceutical company founded in 2020. Specializing in the development, manufacturing, marketing, and distribution of active pharmaceutical ingredients (APIs) and intermediates, Euroapi serves both human and veterinary medicine sectors. The company stands out as a contract development manufacturing organization (CDMO), offering a wide range of services which encompass various methods and compounds critical for drug formulation. It leverages state-of-the-art techniques in solid phase chemistry, particle engineering, and microbial fermentation, among others, to meet the diverse needs of its global clientele.
Products and Services
- Solid Phase Chemistry - Euroapi utilizes this method for synthesizing peptides, providing high purity products essential for various therapeutic applications.
- Particle Engineering - This service involves modifying the size, shape, and morphology of particles to enhance drug formulation, improving solubility, and delivery mechanisms.
- Microbial Fermentation - Leveraging microbial processes to produce APIs and intermediates, this method is crucial for the production of antibiotics, enzymes, and other bioactive molecules.
- Small Molecules Synthesis - Specializing in the synthesis of small molecule drugs, Euroapi offers solutions for a wide variety of diseases and conditions, utilizing innovative synthetic routes and processes.
- Prostaglandins, Steroids, and Hormones - Euroapi manufactures these critical compounds, which are indispensable in treatments ranging from inflammation and pain management to hormone replacement therapies.
- Opiates and Controlled Substances - With tight regulatory compliance, Euroapi provides secure manufacturing of opiates and other controlled substances for therapeutic use, ensuring high standards of quality and safety.
- Lipids - This service focuses on the production of lipids used in drug delivery systems, particularly for RNA-based therapeutics, highlighting Euroapi’s role in advancing modern medicine.
Contact Information
Address: 15 Rue Traversiere, Paris, France, 75012
Phone: 33 1 89 20 62 00
Website: https://www.euroapi.com/en
